常规剂量与高剂量辛伐他汀联合苯磺酸氨氯地平治疗对高血压伴高血脂患者的有效性及安全性对比

Comparison of Effectiveness and Safety Between Conventional Dose and High-Dose Simvastatin Combined with Amlodipine Besylate in the Treatment of Patients with Hypertension and Hyperlipidemia

目的探讨常规剂量与高剂量辛伐他汀联合苯磺酸氨氯地平治疗高血压伴高血脂的有效性及安全性。方法选择2022年1月—2023年10月金乡县人民医院收治60例高血压伴高血脂患者为研究对象,按随机数字表法将其分为对照组和观察组,各30例。对照组采用常规剂量辛伐他汀联合苯磺酸氨氯地平治疗,观察组采用高剂量辛伐他汀联合苯磺酸氨氯地平治疗,两组治疗时间均为3个月。比较两组临床疗效、血压水平、血脂水平及不良反应发生情况。结果观察组治疗总有效率为93.33%,高于对照组的73.33%,差异有统计学意义(P<0.05)。治疗后,观察组舒张压为(80.14±6.79)mmHg(1 mmHg=0.133 kPa)、收缩压为(114.53±12.04)mmHg,均低于对照组的(92.53±8.86)mmHg、(128.39±13.85)mmHg,组间差异有统计学意义(P<0.05);观察组三酰甘油、总胆固醇及低密度脂蛋白胆固醇水平均低于对照组,高密度脂蛋白胆固醇水平高于对照组,组间差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论高剂量辛伐他汀联合苯磺酸氨氯地平治疗高血压伴高血脂患者的效果比常规剂量疗效更加理想,能显著降低患者血压及血脂水平,且用药安全。

Objective To explore the effectiveness and safety of conventional and high-dose simvastatin combined with amlodipine besylate in the treatment of hypertension with hyperlipidemia.Methods Sixty patients with hypertension and hyperlipidemia admitted to Jinxiang County People's Hospital from January 2022 to October 2023 were selected as the research subjects,they were randomly divided into a control group and an observation group,with 30 patients in each group,using a random number table method.The control group was treated with conventional dose of simvastatin combined with amlodipine besylate,while the observation group was treated with high-dose simvastatin combined with amlodipine besylate.The treatment time is all 3 months.Compare the clinical efficacy,blood pressure levels,lipid levels,and adverse reactions between two groups.Results The total effective rate of the observation group was 93.33%,which was higher than 73.33%in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of diastolic blood pressure and systolic blood pressure in the observation group were(80.14±6.79)mmHg(1 mmHg=0.133 kPa)and(114.53±12.04)mmHg,which were lower than(92.53±8.86)mmHg and(128.39±13.85)mmHg in the control group,respectively,the differenceas between the groups were statistically significant(P<0.05);and the levels of triglycerides,total cholesterol,and low-density lipoprotein cholesterol in the observation group were lower than those in the control group,while the level of high-density lipoprotein cholesterol was higher than that in the control group,the differences between the groups were statistically significant(P<0.05).There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion The combination of high-dose simvastatin and amlodipine besylate is more effective than conventional doses in treating patients with hypertension and hyperlipidemia.It can significantly reduce blood pressure and lipid levels in patients,and the medication is safe.